| Date Filed | Type | Description |
| 07/12/2023 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 3,200 shares
@ $18.0016, valued at
$57.6k
Sold 3,897 shares
@ $18.048, valued at
$70.3k
|
|
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 11/02/2022 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 2,100 shares
@ $24.0453, valued at
$50.5k
|
|
| 10/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2022 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 1,329 shares
@ $15.32, valued at
$20.4k
Sold 215 shares
@ $16.2477, valued at
$3.5k
|
|
| 09/23/2022 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 3,275 shares
@ $15.1258, valued at
$49.5k
Sold 1,018 shares
@ $15.0694, valued at
$15.3k
|
|
| 09/19/2022 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 100 shares
@ $15.01, valued at
$1.5k
|
|
| 09/12/2022 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 912 shares
@ $15.1472, valued at
$13.8k
Sold 865 shares
@ $15.0646, valued at
$13k
|
|
| 09/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/01/2021 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Granted 95,148 options to buy
@ $20, valued at
$1.9M
|
|
| 10/28/2021 |
3
| Dowden Nathan J (COO) has filed a Form 3 on Entrada Therapeutics, Inc. |